Video

Dr. Shore on the TERRAIN Trial for Prostate Cancer

Author(s):

Neal D. Shore, MD

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses the results of the TERRAIN trial.

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses the results of the TERRAIN trial.

The TERRAIN trial was a prospective, double-blind study randomizing patients to enzalutamide or bicalutamide. Patients were included who had asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC), Shore explains.

A 10-month radiographic progression-free survival benefit was seen in patients treated with enzalutamide versus bicalutamide. Patients in the enzalutamide arm also saw a decline in prostate-specific antigen levels.

The phase II study, which enrolled 375 patients, demonstrated the advantages of treatment with enzalutamide compared with bicalutamide, Shore says.

<<<

View more from the 2015 AUA Annual Meeting

Related Videos
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Jun Gong, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Marc-Oliver Grimm, MD
Sheldon M. Feldman, MD
Related Content
Jonathan W. Riess, MD, MS
July 26th 2024

Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Christian Behrenbruch PhD, MBA
July 24th 2024

FDA Accepts the New Drug Application for TLX007-CDx Kit in Prostate Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Sarah Sammons, MD
July 22nd 2024

Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium

Pedram Razavi, MD, PhD
July 22nd 2024

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management